Derivative Suit Faults Allergan Board For Rejecting Valeant Bid
Allergan Inc.'s board of directors was hit with a new shareholder derivative class action in California federal court Wednesday alleging they failed to properly consider Valeant Pharmaceuticals International Inc.'s takeover bid...To view the full article, register now.
Already a subscriber? Click here to view full article